Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
Teva Pharmaceutical Industries’ announcement last month to walk away from the Japanese generic business sent shockwaves among its Japanese employees, with Teva Takeda Pharma bearing the brunt of the abrupt decision. The Japan unit has just swung back to profit…
To read the full story
Related Article
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
- And Pharma Chief Pledges Growth Strategy as New Generics Holding Firm Takes Shape
September 5, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- Nippon Chemiphar Signs On to Meiji-Daito Consortium as Talks Accelerate
July 22, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
COMMENTARY
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
- Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
- 9 Drugs Top 100 Billion Yen in FY2025 Japan Sales; Keytruda Retains Crown: Jiho Tally
August 20, 2026
- Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…